Edgewise Therapeutics, Inc.
Support and Resistance Levels
Past performance
News About EWTX
All events for EWTX
All deals for EWTX
Financial Ratios
Financial Statements
EWTX vs Sector & Peers
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado. Website edgewisetx.com
Headquarters Boulder, CO, US